(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stock index futures were higher on Wednesday, after Apple reported strong quarterly results and ahead of a statement from the Federal Reserve. Dow Jones industrial average e-mini futures were up 0.15 percent at 17,539, S&P 500 e-mini futures were up 0.21 percent at 2,064.75 and Nasdaq 100 e-mini futures were up 0.28 percent at 4,645.25.
** APPLE INC, Tuesday close $114.55, +1.27 pct premarket
The iphone maker painted a rosy picture for its new iPhones as it reported quarterly results on Tuesday, but investors were more focused on the company’s next test: topping last year’s record holiday sales.
Breakingviews-Apple: a tech company with Chinese characteristics
Breakingviews-Searching for China consumer bellwethers is futile
** WALGREENS BOOTS ALLIANCE INC, Tuesday close $95.16, -0.38 pct premarket
** RITE AID CORP, Tuesday close $8.67, -8.19 pct premarket
Drugstore chain operator Walgreens, which agreed to buy smaller rival Rite Aid on Tuesday, reported a better-than-expected quarterly profit, helped by lower costs achieved through its cost-cutting plan.
Breakingviews-Investors coax Walgreens Boots to swallow Rite Aid
** TWITTER INC, Tuesday close $31.34, -10.31 pct premarket
The company gave a disappointing revenue forecast and reported slower user growth than expected. The forecast, which came even as Twitter beat third-quarter profit and revenue estimates, suggested that more time is needed for a turnaround as social media competition grows from the likes of Facebook Inc’s FB.O Instagram and Messenger apps. 12 brokerages cut price targets, Stifel raises to “buy” from “neutral”
** NORTHROP GRUMMAN CORP, Tuesday close $180.6, +5.92 pct premarket
Hours after winning a multibillion-dollar contract to build a new U.S. bomber, the company on Wednesday reported higher-than-expected quarterly revenues and earnings and increased its profit outlook for the full year.
** GILEAD SCIENCES INC, Tuesday close $110.96, -1.27 pct premarket
The drugmaker on Tuesday said its quarterly profit rose 70 percent, but sales growth for its hepatitis C drugs flattened as health insurers limited access to the expensive treatments.
** BOSTON SCIENTIFIC CORP, Tuesday close $16.82, +4.04 pct premarket
The medical device maker reported a better-than-expected quarterly profit, helped by strong demand for its surgical products.
** DIAMOND FOODS INC, Tuesday close $34.89, +8.91 pct premarket
Snack food maker Snyder’s-Lance Inc said it will buy Diamond Foods for about $1.27 billion to expand in the “better-for-you” foods category, which includes baked potato chips and fat-free popcorn.
** MACROCURE LTD, Tuesday close $4.26, -71.60 pct premarket
The Israeli biotechnology company said it would “analyze all strategic options” after its cell therapy for hard-to-treat wounds failed a late-stage U.S. study.
** AMGEN INC, Tuesday close $161.98, +0.99 pct premarket
U.S. health regulators on Tuesday approved the drugmaker’s novel cancer immunotherapy for injection into melanoma lesions and lymph nodes of patients with the deadliest form of skin cancer that returns after initial surgery.
** VALEANT PHARMACEUTICALS INTERNATIONAL, Tuesday close $109.54
Activist firm ValueAct is meeting with other large investors in the Canadian drugmaker, as the company aims to rally support amid allegations of improper accounting and aggressive pricing.
** ARENA PHARMACEUTICALS INC, Tuesday close $2.2
The drug developer will shelve some trials related to its weight-loss drug and lay off about 80 employees, or 35 percent of its U.S. workforce, to cut costs and focus on other drugs under development.
** ANTHEM INC, Tuesday close $144.69
The health insurer reported a better-than-expected profit in the third quarter as more people enrolled for its government plans, especially Medicaid.
Reporting by Rosmi Shaji in Bengaluru; Editing by Sriraj Kalluvila